CROs Counting On Biotech Stock Rise, Phase IV Trials To Drive New Business
Executive Summary
Recently enriched biotechnology companies will help the contract research organization market recover from its slump in the coming year, PPD CEO Fred Eshelman, MD, told analysts during an April 20 conference call.
You may also be interested in...
PPD Doubles Personnel For Internal Discovery Of Therapeutic Targets
PPD has "nearly doubled" the number of full-time equivalents in its discovery unit dedicated to R&D for internal projects, CEO Fred Eshelman, MD, told analysts during an April 17 conference call.
PPD Doubles Personnel For Internal Discovery Of Therapeutic Targets
PPD has "nearly doubled" the number of full-time equivalents in its discovery unit dedicated to R&D for internal projects, CEO Fred Eshelman, MD, told analysts during an April 17 conference call.
Sponsors' Failure To Complete Phase IV Studies Should Draw Penalties - HRG
Public Citizen's Health Research Group is calling for FDA to seek authority to levy money penalties in cases where sponsors have failed to complete postmarketing studies requested by the agency.